Publications

Unified gene expression signature of novel NPM1 exon 5 mutations in acute myeloid leukemia.Lisi V, Blanchard E, Vladovsky M, Audemard E, Ferghaly A, Lemieux S, Hébert J, Sauvageau G, Lavallée VPBlood Adv 2022-09-13;6(17):5160-5164.

HMGA2 expression defines a subset of human AML with immature transcriptional signature and vulnerability to G2/M inhibition.Moison C, Spinella JF, Chagraoui J, Lavallée VP, Lehnertz B, Thiollier C, Boivin I, Mayotte N, MacRae T, Marinier A, Hébert J, Sauvageau GBlood Adv 2022-08-23;6(16):4793-4806.

Donor Age and Non-Relapse Mortality: Study of Their Association after HLA-Matched Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome.Kadri Y, Phan M, Bambace N, Bernard L, Cohen S, Delisle JS, Kiss T, Lachance S, Roy DC, Sauvageau G, Veilleux O, Roy J, Ahmad ICurr Oncol 2022-08-22;29(8):5955-5962.

Hyaluronic acid-GPRC5C signalling promotes dormancy in haematopoietic stem cells.Zhang YW, Mess J, Aizarani N, Mishra P, Johnson C, Romero-Mulero MC, Rettkowski J, Schönberger K, Obier N, Jäcklein K, Woessner NM, Lalioti ME, Velasco-Hernandez T, Sikora K, Wäsch R, Lehnertz B, Sauvageau G, Manke T, Menendez P, Walter SG, Minguet S, Laurenti E, Günther S, Grün D, Cabezas-Wallscheid NNat Cell Biol 2022-07-01;24(7):1038-1048.

UM171 Expansion of Cord Blood Improves Donor Availability and HLA Matching For All Patients, Including Minorities.Dumont-Lagacé M, Feghaly A, Meunier MC, Finney M, Van't Hof W, Masson Frenet E, Sauvageau G, Cohen STransplant Cell Ther 2022-07-01;28(7):410.e1-410.e5.

CEACAM1 is a novel culture-compatible surface marker of expanded long-term reconstituting hematopoietic stem cells.Ansari U, Tomellini E, Chagraoui J, Lehnertz B, Mayotte N, Bordeleau ME, Roux PP, Sauvageau GBlood Adv 2022-06-28;6(12):3626-3631.

Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia.Baran N, Lodi A, Dhungana Y, Herbrich S, Collins M, Sweeney S, Pandey R, Skwarska A, Patel S, Tremblay M, Kuruvilla VM, Cavazos A, Kaplan M, Warmoes MO, Veiga DT, Furudate K, Rojas-Sutterin S, Haman A, Gareau Y, Marinier A, Ma H, Harutyunyan K, Daher M, Garcia LM, Al-Atrash G, Piya S, Ruvolo V, Yang W, Shanmugavelandy SS, Feng N, Gay J, Du D, Yang JJ, Hoff FW, Kaminski M, Tomczak K, Eric Davis R, Herranz D, Ferrando A, Jabbour EJ, Emilia Di Francesco M, Teachey DT, Horton TM, Kornblau S, Rezvani K, Sauvageau G, Gagea M, Andreeff M, Takahashi K, Marszalek JR, Lorenzi PL, Yu J, Tiziani S, Hoang T, Konopleva MNat Commun 2022-05-19;13(1):2801.

CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia.He L, Arnold C, Thoma J, Rohde C, Kholmatov M, Garg S, Hsiao CC, Viol L, Zhang K, Sun R, Schmidt C, Janssen M, MacRae T, Huber K, Thiede C, Hébert J, Sauvageau G, Spratte J, Fluhr H, Aust G, Müller-Tidow C, Niehrs C, Pereira G, Hamann J, Tanaka M, Zaugg JB, Pabst CEMBO Mol Med 2022-03-07:e14990.

Real-World Outcomes of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Era of Novel Therapies: A Canadian Perspective.Veilleux O, Claveau JS, Alaoui H, Roy J, Ahmad I, Delisle JS, Kiss T, Bambace NM, Bernard L, Cohen S, Sauvageau G, Fleury I, Mollica L, Roy DC, Serroukh Y, Lachance STransplant Cell Ther 2022-03-01;28(3):145-151.

Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study.LeBlanc R, Ahmad I, Terra R, Boudreault JS, Ogez D, Lamore K, Delisle JS, Bambace N, Bernard L, Cohen S, Kiss T, Lachance S, Landais S, Lemieux-Blanchard E, Sauvageau G, Sebag M, Roy DC, Roy JBone Marrow Transplant 2022-02-01;57(2):252-260.

Page précédente   |   Page suivante

Suivez l'IRIC

Logo UdeM